NCT04975958: Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Serine-Threonine Kinase Inhibitor, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have received at least one line of prior systemic therapy or no alternative therapy to prolong survival exists
Exclusions: Patients who have received more than 4 prior lines of systemic therapy for advanced disease; Patients with known active unstable CNS metastases; Patients with leptomeningeal disease; Patients who have received previous treatment with any mTOR inhibitors (e.g. Afinitor/everolimus) or PI3K pathway inhibitors (e.g. Piqray/alpelisib)

Comments are closed.

Up ↑